Johnson & Johnson (JNJ)
NYSE • Healthcare
August 18, 2026 at 20:00 UTC
About Johnson & Johnson
Johnson & Johnson develops and sells healthcare products across pharmaceuticals and medical technology, with shares listed on the NYSE under JNJ. In FY2025 it generated $94.2 billion in revenue. The company operates in healthcare as a maker of medicines and care-delivery products for hospitals, medical professionals, and retail channels.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Johnson & Johnson's Technical Indicators Summary
Johnson & Johnson shows a constructive technical profile with the price comfortably above its short- and medium-term moving averages and well above the 200-day average, supporting the strong buy stance. Momentum indicators are positive overall, with a bullish MACD and a high CCI while RSI sits in upper-neutral territory, even as Williams %R signals short-term overbought conditions. Trend strength is moderate with an ADX below strong-trend territory, and volatility is restrained given an ATR near two percent. Healthy OBV accumulation and a pivot level below the current price add confirmation. Technical takeaway: Strong buy bias backed by broad moving-average support and accumulation.
| Indicator | Value |
|---|---|
RSI (14) | 66.68 |
Stochastic %K (14, 3, 3) | 66.91 |
CCI (20) | 175.57 |
WPR (14) | -2.91 |
Momentum (10) | 16.18 |
MFI | 43.97 |
MACD Level (12, 26) | 3.18 |
Bollinger Bands | $251.59 - $269.43 |
ATR (14) | $5.86 (2.16%) |
ADX (14) | 18.66 |
OBV | 231,926,201 |
Classic Pivot Point | $261.55 |
Fibonacci Pivot Point | $261.55 |
Simple Moving Averages | $230.58 - $261.22(5 indicators) |
Exponential Moving Averages | $229.07 - $262.24(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
Into the close, JNJ still reflected its 3.33% upside gap from yesterday. The session closed with mild sector strength (1.59%), slightly supporting risk appetite. JNJ gains on FDA clearance for MONARCH QUEST 3 AI bronchoscopy upgrade expanding robotic diagnostics.
Trading Volume
Above 10d avg 6.3M
6.8M
vs S&P 500 Today
Strong Outperformance
+3.93%
52-Week Position
Near highs
96.3%
Updated: August 18, 2026 at 20:18 UTC
Quote Summary
JNJ Headlines
J&J outlines $5.5bn talc settlement plan
July 28, 2026
J&J lifts 2026 outlook after Q2 earnings
July 15, 2026
Health Care Lags SPY At 24-Year Low
May 18, 2026
Nasdaq 100 Soars As JNJ Correlation Flips
May 15, 2026